RxDoctor Payments Data

Padma Shukla, MD

Cardiovascular Disease · Reston, VANPI 1831299783

Payments from drug & device makers

$3,474in general payments, 2019–2025

Across 82 payments — averaging $42.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Johnson & Johnson$755
  • Novartis$238
  • Merck$227
  • AbbVie$188
  • Bayer$183
  • plus $617 from 12 others

What the payments were for

  • Food & beverage$3,44299%
  • Education$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,474 in reported general payments places this provider in the 65th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$196,225
Medicare patients
559
Services billed
2,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$51,332
EliquisApixaban30$33,664
XareltoRivaroxaban20$23,621
JardianceEmpagliflozin22$16,838
Colesevelam Hcl11$4,446
JanumetSitagliptin Phos/Metformin Hcl11$1,885
Nebivolol Hcl14$1,244
Levothyroxine Sodium28$989
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide18$775
Metoprolol Succinate61$757
Atorvastatin Calcium70$714
Labetalol Hcl11$679
Doxazosin Mesylate49$610
Amlodipine Besylate80$487
Hydralazine Hcl29$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,266$51,33230 claims
PfizerEliquis$48$33,66430 claims
Johnson & JohnsonXarelto$755$23,62120 claims
Boehringer IngelheimJardiance$123$16,83822 claims
MerckJanumet$227$1,88511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Reston

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →